Mechanisms that might contribute to the cognitive benefits of
Mannatech’s Ambrotose® polysaccharides are
presented
COPPELL, Texas--(BUSINESS WIRE)--Apr. 4, 2012--
Mannatech,
Incorporated (NASDAQ: MTEX),
the leading innovator and provider of nutritional supplements based on Real
Food Technology® solutions, announced the presentation of
product research at the prestigious 10th Jenner Glycobiology
and Medicine Symposium, which was held in The Hague, the Netherlands,
March 31–April 3, 2012. The pre-clinical study showed that intake of
Advanced Ambrotose® powder had positive effects in the brain
on the expression of genes associated with the regulation of learning,
memory and mood.*(1)
“We were pleased to be invited to present our science at this
prestigious event,” said Dr. Robert Sinnott, CEO and Chief Science
Officer at Mannatech. “The United Kingdom’s Royal Society of Medicine
has been hosting these meetings—devoted to providing a forum for
scientists and clinicians to disseminate the findings of current
leading-edge research in both novel and classic fields of
glycobiology—for over 20 years. Our interesting, preliminary research
presents findings that are highly compatible with multiple controlled
human clinical studies, which indicate that intake of Ambrotose®
products provides significant cognitive benefits to healthy adults.”*
The study was authored by Dr. Erika N. Nelson, Jane Ramberg and Dr.
Sinnott. Dr. Nelson earned her BS in Genetics from the University of
Kansas in Lawrence and went on to obtain her PhD in Neuroscience at the
University of Texas Southwestern Medical Center in Dallas. She has
published a number of papers on neurodevelopmental disorders and brain
epigenetics. A candidate for a Masters of Business Administration at the
University of Texas at Dallas, Dr. Nelson is also a consultant for
Mannatech. Jane Ramberg is Director of Product Substantiation at
Mannatech.
The 10th Jenner Glycobiology and Medicine Symposium brought
together scientists from around the world, including many thought
leaders in the field of glycobiology. More information about the meeting
can be found here: http://www.rsm.ac.uk/jenner10/.
Individuals interested in Mannatech’s products or exploring its business
opportunity are encouraged to learn more at Mannatech.com.
About Mannatech
Mannatech, Incorporated, develops high-quality health, weight and
fitness, and skin care products that are based on the solid foundation
of nutritional science and development standards. Mannatech is dedicated
to its platform of Social Entrepreneurship based on the foundation of
promoting, aiding and optimizing nutrition where it is needed most
around the world. Mannatech’s proprietary products are available through
independent sales Associates around the globe including the United
States, Canada, South Africa, Australia, New Zealand, Austria, Denmark,
Germany, Norway, Sweden, the Netherlands, the United Kingdom, Japan,
Taiwan, Singapore, Estonia, Finland, the Republic of Ireland, Czech
Republic, the Republic of Korea, Mexico and Namibia. For more
information, visit Mannatech.com.
Please note: This release contains “forward-looking statements”
within the meaning of Section 27A of the Securities Act of 1933, as
amended, Section 21E of the Securities Exchange Act of 1934, as amended,
and the Private Securities Litigation Reform Act of 1995. These
forward-looking statements generally can be identified by use of phrases
or terminology such as “believe,” “intend” or other similar words or the
negative of such terminology. Similarly, descriptions of Mannatech’s
objectives, strategies, plans, goals or targets contained herein are
also considered forward-looking statements. Mannatech believes this
release should be read in conjunction with all of its filings with the
United States Securities and Exchange Commission and cautions its
readers that these forward-looking statements are subject to certain
events, risks, uncertainties and other factors. Some of these factors
include, among others, Mannatech’s inability to attract and retain
Associates and Members, increases in competition, litigation, regulatory
changes and its planned growth into new international markets. Although
Mannatech believes that the expectations, statements and assumptions
reflected in these forward-looking statements are reasonable, it
cautions readers to always consider all of the risk factors and any
other cautionary statements carefully in evaluating each forward-looking
statement in this release, as well as those set forth in its latest
Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other
filings filed with the United States Securities and Exchange Commission,
including its current reports on Form 8-K. All of the forward-looking
statements contained herein speak only as of the date of this release.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat, cure
or prevent any disease.
1. Nelson EN, Ramberg JE, Sinnott RA. Brain-specific effects of Ambrotose®
products: a preliminary animal study to investigate cognitive benefits
found in humans. Poster Presentation at the 10th Jenner Glycobiology and
Medicine Symposium, The Hague, the Netherlands, March 31–April 3, 2012.
Source: Mannatech, Incorporated
Mannatech, Incorporated
Brett Duncan, 972-471-7367
bduncan@mannatech.com